Ethinylestradiol sulfonate/norethisterone acetate

Ethinylestradiol sulfonate /
norethisterone acetate
	Ethinylestradiol sulfonate (top) and; norethisterone acetate (bottom)
Combination of
Ethinylestradiol sulfonate	Estrogen
Norethisterone acetate	Progestogen
Clinical data
Trade names	Deposiston
Other names	EES/NETA
Routes of; administration	By mouth
Drug class	Estrogen; Progestogen
Identifiers
CAS Number	54958-72-4;

Ethinylestradiol sulfonate/norethisterone acetate (EES/NETA), sold under the brand name Deposiston, is a combination medication of ethinylestradiol sulfonate (EES), an estrogen, and norethisterone acetate (NETA), a progestin, which was used as a combined birth control pill for women.^[1] It was formulated as oral tablets and contained 1 mg EES and 5 mg NETA per tablet.^[2]^[3]^[1] The medication had a long-lasting depot effect and was taken only once per week, for a total of four tablets per cycle.^[1]^[2] It was developed and marketed by Jenapharm and was previously available in Germany.^[2]^[1]^[3] EES/NETA was introduced for medical use in 1978.^[1]

References

^ ^a ^b ^c ^d ^e Schwarz S, Onken D, Schubert A (July 1999). "The steroid story of Jenapharm: from the late 1940s to the early 1970s". Steroids. 64 (7): 439–45. doi:10.1016/S0039-128X(99)00003-3. PMID 10443899. S2CID 40156824. 6.2. New estrogens. In 1967, Jenapharm, in conjunction with the Academy of Sciences (Kurt Ponsold, Gu¨nter Bruns, and Kurt Schubert in Jena and Hans Schick and Bernard Lu¨cke in Berlin), started a program of searching for new estrogens. [...] orally administered, strongly active estrogens with a depot effect. [...] the second objective was successfully attained. The rationale that an a-branched alkanesulfonic acid ester of ethinyl estradiol with a medium chain length should lead to a depot effect without the danger of active ingredient accumulation on longer usage [15] led in 1978 to the first once-a-week oral contraceptive (DEPOSISTONt), a combination of ethinylestradiol 3-isopropylsulfonate (17) and norethisterone acetate [16]. TURISTERONt, an estrogenic monotherapy with compound 17 that can still justify its position today [17], followed in 1980, as a therapy of prostate cancer. [...]
^ ^a ^b ^c Freimut A. Leidenberger (17 April 2013). Klinische Endokrinologie für Frauenärzte. Springer-Verlag. pp. 542–. ISBN 978-3-662-08110-5.
^ ^a ^b Muller (19 June 1998). European Drug Index: European Drug Registrations, Fourth Edition. CRC Press. pp. 338–. ISBN 978-3-7692-2114-5.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.